Sponsor Pipeline

Relay Therapeutics Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
4
Active Trials
4
Recruiting
1
Phase 3
2
Disease Areas
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-08-13 NCT06789913
A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children…		 Trial sites expanded: 34 -> 40 locations
2026-08-06 NCT06982521
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for…		 Trial sites expanded: 211 -> 222 locations
Active Trials by Phase
Phase 3
1
Phase 2
1
Phase 1
2
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06982521 Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for… PIK3CA Mutation Recruiting
Phase 2
NCT06789913 A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children… PIK3CA-Related Overgrowth Spectrum (PROS) Recruiting
Phase 1
NCT05216432 First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in… PIK3CA Mutation Recruiting
NCT07584226 A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors Advanced NRAS-Mutant Melanoma Recruiting
Disease Areas
Breast Cancer (2) Melanoma (1)
Get alerts when Relay Therapeutics's trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free